| Nov 4 |
ALX Oncology Announces November Investor Conference Participation
|
| Nov 1 |
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
|
| Oct 10 |
Millennium Management LLC Reduces Stake in ALX Oncology Holdings Inc
|
| Sep 12 |
ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations
|
| Sep 9 |
ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
|
| Sep 4 |
ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
|
| Aug 27 |
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
|
| Aug 9 |
ALX Oncology GAAP EPS of -$0.76 in-line
|
| Aug 8 |
ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
| Aug 6 |
ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
|
